Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

In Vitro Combined Modality Treatment of Prostate Carcinoma Cells with 17-(allylamino)-17-demethoxygeldanamycin and Ionizing Radiation

HANS-JOACHIM OCHEL and GÜNTHER GADEMANN
Anticancer Research May 2006, 26 (3A) 2085-2091;
HANS-JOACHIM OCHEL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hans-joachim.ochel{at}medizin.uni-magdeburg.de
GÜNTHER GADEMANN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: The effect of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG), a benzoquinone-ansamycin-type Hsp90-inhibitor, on the expression of focal adhesion kinase (FAK) and, when combined with ionizing radiation, on the clonogenicity of prostate cancer cells were determined. Materials and Methods: FAK was analyzed by Western immunoblot. Prostate carcinoma cells were exposed either to 17-AAG alone or combined with a single radiation fraction of 3 Gy. Results: FAK concentrations were reduced by 17-AAG in a time-dependent manner. Treatment with 100 nM 17-AAG for 24 h reduced clonogenicity by 90%. The plot of surviving fraction versus radiation energy dose yielded roughly parallel graphs for solvent- and 17-AAG-treated cells. Conclusion: 17-AAG induced rapid degradation of FAK. A single radiation fraction of 3 Gy did not enhance the dose-dependent drug-effect on survival. In this sequence, the combined effect of both modalities towards clonogenicity was largely additive.

  • Prostate cancer
  • heat shock protein 90
  • focal adhesion kinase
  • irradiation

Footnotes

  • Received January 3, 2006.
  • Accepted March 14, 2006.
  • Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 26, Issue 3A
May-June 2006
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro Combined Modality Treatment of Prostate Carcinoma Cells with 17-(allylamino)-17-demethoxygeldanamycin and Ionizing Radiation
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
In Vitro Combined Modality Treatment of Prostate Carcinoma Cells with 17-(allylamino)-17-demethoxygeldanamycin and Ionizing Radiation
HANS-JOACHIM OCHEL, GÜNTHER GADEMANN
Anticancer Research May 2006, 26 (3A) 2085-2091;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
In Vitro Combined Modality Treatment of Prostate Carcinoma Cells with 17-(allylamino)-17-demethoxygeldanamycin and Ionizing Radiation
HANS-JOACHIM OCHEL, GÜNTHER GADEMANN
Anticancer Research May 2006, 26 (3A) 2085-2091;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms
  • Google Scholar

More in this TOC Section

  • Silencing of β-TrCP2 Suppresses Growth and G1/S Cell Cycle Progression in Non-small Cell Lung Carcinoma Cells
  • Molecular Features of Gastrointestinal Stromal Tumors: A Single Referral Cancer Center Experience
  • Targeting AURKB Attenuates Tumor Growth in MYC-driven Lung Adenocarcinoma
Show more Experimental Studies
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire